Methods blog · Drug Repositioning & Network Medicine
Network proximity & separationCyclosporine + selinexor against SARS-CoV-2: a network-medicine case for complementary exposure
Interactome-based proximity, functional proximity and topological separation show that cyclosporine and selinexor target complementary SARS-CoV-2 modules, viral replication and cytokine storm.
#network medicine#drug combination#SARS-CoV-2#interactome#network separation
Two hallmark features of severe COVID-19 are enhanced viral replication and a subsequent cytokine storm. Two existing drugs had each shown activity against SARS-CoV-2 through one of these routes:
- cyclosporine, an immunosuppressant (relevant to the cytokine storm);
- selinexor, an inhibitor of the nuclear export protein XPO1 (relevant to viral replication).
Because the pathology is multifactorial, a monotherapy is unlikely to be optimal. We asked whether network medicine supports combining them.
The framework
All analyses run on an integrated human interactome. For each drug we define a drug module (its targets in the network) and compare it with SARS-CoV-2 disease modules (host proteins perturbed by infection).
- Disease proximity: are a drug’s targets closer to the disease module than random target sets? We compute a network distance and assess it against randomised expectations.
- Functional proximity: do the drug and disease modules share enriched biological functions?
- Topological separation between the two drug modules \(A\) and \(B\), for example with the separation measure widely used in network medicine:
where \(\langle d_{AB}\rangle\) is the mean shortest distance between the two modules and \(\langle d_{AA}\rangle\) and \(\langle d_{BB}\rangle\) are the within-module distances. A positive \(s_{AB}\) means the two drugs act on topologically separate neighbourhoods.
All results are tested for statistical significance.
Findings
- Both drug-target modules are highly proximal to SARS-CoV-2 disease modules, topologically and functionally, and significantly so for each drug on its own.
- Functional enrichment shows the two drugs target functions related to viral replication and cytokine storm, respectively.
- The two drug modules are well separated in the network. Each drug hits the disease module, but from a different side: a pattern known as complementary exposure, which network-medicine studies have associated with effective combinations.
Implication
Cyclosporine plus selinexor is a rational candidate combination that warrants in vitro and in vivo testing, and ultimately clinical evaluation. The analysis also illustrates the general workflow we first built into COVID-CDR, now being extended to cancer in the proposed Onco-CDR platform.